Section I
101 – 110 of 4892
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer : Working Group 3: Subcategorization of T1 Bladder Cancer
(
- Contribution to journal › Article
-
Mark
FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology
(
- Contribution to journal › Article
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guérin Instillations for Bladder Cancer : Time To Reconsider the Evidence and Open the Quinolone Box?
(
- Contribution to journal › Scientific review
-
Mark
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
(
- Contribution to journal › Article
-
Mark
Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases
(
- Contribution to journal › Article
-
Mark
Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma
(
- Contribution to journal › Article
-
Mark
The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Tumor suppressor role of the complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas
(
- Contribution to journal › Article